Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2007

01-04-2007 | Original Paper

Prioritising drug and therapeutics committee (DTC) decisions: a national survey

Authors: Ee Lyn Tan, Richard O. Day, Jo-anne E. Brien

Published in: International Journal of Clinical Pharmacy | Issue 2/2007

Login to get access

Abstract

Objective

A national survey was conducted to explore stakeholder opinions about: (1) the domains of activity and criteria used to determine “important” decisions; (2) the “importance” of Drug and Therapeutics Committee (DTC) decisions as an appropriate approach for prioritising implementation and actions and (3) how DTC decisions could be prioritised for action.

Setting

This is a study of DTCs conducted in the Australian health care setting.

Methods

A semi-structured questionnaire was sent to Directors of Pharmacies or Chief Pharmacists in Australian hospitals. Questionnaires could be returned by email or by fax. Two weeks after initial mail-out, non-responders were followed-up. Responses were collated and analysed using descriptive statistics. Free-text responses were collated. QSR NVivo© was used as a data management tool.

Results

The response rate was 61%. All respondents indicated that “patient safety” was a domain of importance for a decision. Other domains of important DTC decisions include: “ensuring the practice of evidence based medicine within their institution” (94%), “cost” (93%), “ensure practice according to legislative requirements” (87%). Most respondents agreed that some DTC decisions were more important than others. Given constraints on time and resources, the majority agreed that DTC decisions should be prioritised for implementation, although most had no suggestions about how this could be done. Some suggested that the domains of importance could be the basis for priority assignment.

Conclusion

Currently DTC decisions and policies are implemented in an ad hoc manner. As a result implementation may be incomplete and ineffective, and may pose a risk of serious consequences in patient care. This study identifies the domains or criteria of DTC decisions so that DTCs may allocate scarce resources to the systematic implementation of important decisions.
Literature
1.
go back to reference Miller B, Plumridge R. Drug and therapeutics committees in Australian hospitals: an assessment of effectiveness. Aust J Hosp Pharm 1983; 13(2):61–4. Miller B, Plumridge R. Drug and therapeutics committees in Australian hospitals: an assessment of effectiveness. Aust J Hosp Pharm 1983; 13(2):61–4.
2.
go back to reference Weekes L, Brooks C. Drug and therapeutics committees in Australia: expected and actual performance. Br J Clin Pharmacol 1996; 42(5):551–7.PubMed Weekes L, Brooks C. Drug and therapeutics committees in Australia: expected and actual performance. Br J Clin Pharmacol 1996; 42(5):551–7.PubMed
3.
go back to reference Holloway K, Green T. Drug and therapeutics committees: a practical guide. Geneva: World Health Organisation. 2003 [Available from: mednet2.who.int/tbs/rational/s4882e.pdf]. Holloway K, Green T. Drug and therapeutics committees: a practical guide. Geneva: World Health Organisation. 2003 [Available from: mednet2.who.int/tbs/rational/s4882e.pdf].
4.
go back to reference Heemink I, Molero-Montes M, Tabit E, et al. Review of the functioning of P&T committees in Boston-area hospitals—Part 1. NJ: Quadrant Healthcom Inc.; 1999. Heemink I, Molero-Montes M, Tabit E, et al. Review of the functioning of P&T committees in Boston-area hospitals—Part 1. NJ: Quadrant Healthcom Inc.; 1999.
5.
go back to reference Abramowitz P. Controlling financial variables—changing prescribing patterns. Am J Hosp Pharm 1984; 41:503–15.PubMed Abramowitz P. Controlling financial variables—changing prescribing patterns. Am J Hosp Pharm 1984; 41:503–15.PubMed
6.
go back to reference Yapp P, Steere N. The role and impact of the drug and therapeutics committee on drug utilisation in hospital. Aust J Hosp Pharm 1980; 10(4):152–3. Yapp P, Steere N. The role and impact of the drug and therapeutics committee on drug utilisation in hospital. Aust J Hosp Pharm 1980; 10(4):152–3.
7.
go back to reference American Society of Hospital Pharmacists. ASHP statement on the pharmacy and therapeutics committees. Am J Hosp Pharm 1978; 35:813–4. American Society of Hospital Pharmacists. ASHP statement on the pharmacy and therapeutics committees. Am J Hosp Pharm 1978; 35:813–4.
8.
go back to reference Schein E. Organizational culture and leadership. 2nd ed. San Francisco: Jossey-Bass. 1997. ISBN: 0787903620. Schein E. Organizational culture and leadership. 2nd ed. San Francisco: Jossey-Bass. 1997. ISBN: 0787903620.
9.
go back to reference Summers K, Szeinbach S. Formularies: the role of pharmacy and therapeutics (P&T) Committees. Clin Ther 1993; 15(2):433–41.PubMed Summers K, Szeinbach S. Formularies: the role of pharmacy and therapeutics (P&T) Committees. Clin Ther 1993; 15(2):433–41.PubMed
10.
go back to reference Wade W, Spruill WJ, Taylor AT, et al. The expanding role of pharmacy and therapeutics committees—The 1990s and beyond. Phamacoecon 1996; 10(2):123–6. Wade W, Spruill WJ, Taylor AT, et al. The expanding role of pharmacy and therapeutics committees—The 1990s and beyond. Phamacoecon 1996; 10(2):123–6.
11.
go back to reference Tan E, Day R, Brien J. Drug and therapeutics committees—are they fulfilling their potential to improve the quality use of medicines? Int J Pharm Pract 2003; 11:175–81.CrossRef Tan E, Day R, Brien J. Drug and therapeutics committees—are they fulfilling their potential to improve the quality use of medicines? Int J Pharm Pract 2003; 11:175–81.CrossRef
12.
go back to reference Tan E, Day R, Brien J. Stakeholder opinions on the implementation of drug and therapeutics committee decisions. J Pharm Pract Res 2004; 34:178–82. Tan E, Day R, Brien J. Stakeholder opinions on the implementation of drug and therapeutics committee decisions. J Pharm Pract Res 2004; 34:178–82.
13.
go back to reference Tan E, Day R, Brien J. Perspectives on drug and therapeutics committee (DTC) policy implementation. Res Soc Adm Pharm 2005; 1:526–45. Tan E, Day R, Brien J. Perspectives on drug and therapeutics committee (DTC) policy implementation. Res Soc Adm Pharm 2005; 1:526–45.
14.
go back to reference Society of Hospital Pharmacists of Australia (2004) Directory of hospital pharmacy and pharmaceutical organisations. The Society of Hospital Pharmacists of Australia, SHPA, Australia. Society of Hospital Pharmacists of Australia (2004) Directory of hospital pharmacy and pharmaceutical organisations. The Society of Hospital Pharmacists of Australia, SHPA, Australia.
15.
go back to reference Tenni P, Hughes J. National survey of clinical pharmacy services. Aust J Hosp Pharm 1996; 26(4):416–27. Tenni P, Hughes J. National survey of clinical pharmacy services. Aust J Hosp Pharm 1996; 26(4):416–27.
16.
go back to reference Weekes L, Day R. The application of adverse drug reaction (ADR) data to drug choice decisions made by pharmacy and therapeutics (P&T) committees: an Australian perspective. Drug Saf 1998; 18(3):153–9.PubMedCrossRef Weekes L, Day R. The application of adverse drug reaction (ADR) data to drug choice decisions made by pharmacy and therapeutics (P&T) committees: an Australian perspective. Drug Saf 1998; 18(3):153–9.PubMedCrossRef
17.
go back to reference The University of York. Effective health care: getting evidence into practice. London: The Royal Society of Medicine Press, 1999. p. 1–16. The University of York. Effective health care: getting evidence into practice. London: The Royal Society of Medicine Press, 1999. p. 1–16.
18.
go back to reference Davidoff F, Haynes B, Sackett D, et al. Evidence based medicine. BMJ 1995; 310:1085–6.PubMed Davidoff F, Haynes B, Sackett D, et al. Evidence based medicine. BMJ 1995; 310:1085–6.PubMed
19.
go back to reference Commonwealth Department of Health and Aged Care. National medicines policy 2000. Canberra: Publications Production Unit (Public Affairs, Parliamentary and Access Branch); 1999. Commonwealth Department of Health and Aged Care. National medicines policy 2000. Canberra: Publications Production Unit (Public Affairs, Parliamentary and Access Branch); 1999.
20.
go back to reference Roughead E, Semple S. Second national report on patient safety: improving medication safety. Australian Council for Safety and Quality in Healthcare; 2002. Roughead E, Semple S. Second national report on patient safety: improving medication safety. Australian Council for Safety and Quality in Healthcare; 2002.
21.
go back to reference Weekes L. Organisational structures to promote quality use of medicines, in school of community medicine, faculty of medicine. PhD thesis, Sydney: University of New South Wales; 2000. p. 354. Weekes L. Organisational structures to promote quality use of medicines, in school of community medicine, faculty of medicine. PhD thesis, Sydney: University of New South Wales; 2000. p. 354.
Metadata
Title
Prioritising drug and therapeutics committee (DTC) decisions: a national survey
Authors
Ee Lyn Tan
Richard O. Day
Jo-anne E. Brien
Publication date
01-04-2007
Publisher
Kluwer Academic Publishers
Published in
International Journal of Clinical Pharmacy / Issue 2/2007
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-006-9074-y

Other articles of this Issue 2/2007

International Journal of Clinical Pharmacy 2/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.